It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Naïve CD4+ T cells coordinate the immune response by acquiring an effector phenotype in response to cytokines. However, the cytokine responses in memory T cells remain largely understudied. Here we use quantitative proteomics, bulk RNA-seq, and single-cell RNA-seq of over 40,000 human naïve and memory CD4+ T cells to show that responses to cytokines differ substantially between these cell types. Memory T cells are unable to differentiate into the Th2 phenotype, and acquire a Th17-like phenotype in response to iTreg polarization. Single-cell analyses show that T cells constitute a transcriptional continuum that progresses from naïve to central and effector memory T cells, forming an effectorness gradient accompanied by an increase in the expression of chemokines and cytokines. Finally, we show that T cell activation and cytokine responses are influenced by the effectorness gradient. Our results illustrate the heterogeneity of T cell responses, furthering our understanding of inflammation.
Cytokines critically control the differentiation and functions of activated naïve and memory T cells. Here the authors show, using multi-omics and single-cell analyses, that naïve and memory T cells exhibit distinct cytokine responses, in which an ‘effectorness gradient’ is depicted by a transcriptional continuum, which shapes the downstream genetic programs.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 Wellcome Genome Campus, Wellcome Sanger Institute, Hinxton, UK; Wellcome Genome Campus, Open Targets, Cambridge, UK
2 The Institute of Cancer Research, Functional Proteomics, London, UK (GRID:grid.18886.3f) (ISNI:0000 0001 1271 4623)
3 Wellcome Genome Campus, Wellcome Sanger Institute, Hinxton, UK (GRID:grid.18886.3f); Wellcome Genome Campus, Open Targets, Cambridge, UK (GRID:grid.18886.3f)
4 GSK R&D, Biostatistics, Stevenage, UK (GRID:grid.18886.3f)
5 GSK R&D, Functional Genomics, Medicinal Science and Technology, Stevenage, UK (GRID:grid.18886.3f)
6 GSK R&D, Human Genetics, Stevenage, UK (GRID:grid.18886.3f)
7 R&D Translational Biology, Biogen, Human Target Validation Core, Cambridge, USA (GRID:grid.417832.b) (ISNI:0000 0004 0384 8146)
8 GSK R&D, Adaptive Immunity RU, Stevenage, UK (GRID:grid.417832.b)
9 GSK R&D, Novel Human Genetics, Stevenage, UK (GRID:grid.417832.b)